A global Phase 3 trial of BFI-751
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors BioFactura
- 11 Sep 2023 According to BioFactura media release, this trial to start early 2024
- 14 Jul 2023 New trial record